172 related articles for article (PubMed ID: 37229566)
21. Tamoxifen as a potential antileishmanial agent: efficacy in the treatment of Leishmania braziliensis and Leishmania chagasi infections.
Miguel DC; Zauli-Nascimento RC; Yokoyama-Yasunaka JK; Katz S; Barbiéri CL; Uliana SR
J Antimicrob Chemother; 2009 Feb; 63(2):365-8. PubMed ID: 19095684
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of the in vitro and in vivo antileishmanial activity of a chloroquinolin derivative against Leishmania species capable of causing tegumentary and visceral leishmaniasis.
Soyer TG; Mendonça DVC; Tavares GSV; Lage DP; Dias DS; Ribeiro PAF; Perin L; Ludolf F; Coelho VTS; Ferreira ACG; Neves PHAS; Matos GF; Chávez-Fumagalli MA; Coimbra ES; Pereira GR; Coelho EAF; Antinarelli LMR
Exp Parasitol; 2019 Apr; 199():30-37. PubMed ID: 30817917
[TBL] [Abstract][Full Text] [Related]
23. Development of topical liposomes containing miltefosine for the treatment of Leishmania major infection in susceptible BALB/c mice.
Kavian Z; Alavizadeh SH; Golmohamadzadeh S; Badiee A; Khamesipour A; Jaafari MR
Acta Trop; 2019 Aug; 196():142-149. PubMed ID: 31103698
[TBL] [Abstract][Full Text] [Related]
24. Generation of luciferase-expressing Leishmania infantum chagasi and assessment of miltefosine efficacy in infected hamsters through bioimaging.
Reimão JQ; Oliveira JC; Trinconi CT; Cotrim PC; Coelho AC; Uliana SR
PLoS Negl Trop Dis; 2015 Feb; 9(2):e0003556. PubMed ID: 25679212
[TBL] [Abstract][Full Text] [Related]
25. Stachys lavandulifolia Vahl. exhibits promising in vitro and in vivo antileishmanial activity against Leishmania major infection.
Alanazi AD; Albalawi AE; Almohammed HI; Shater AF
Trop Biomed; 2022 Sep; 39(3):412-420. PubMed ID: 36214438
[TBL] [Abstract][Full Text] [Related]
26. Combination of paromomycin plus human anti-TNF-α antibodies to control the local inflammatory response in BALB/ mice with cutaneous leishmaniasis lesions.
Schwartz J; Moreno E; Calvo A; Blanco L; Fernández-Rubio C; Sanmartín C; Nguewa P; Irache JM; Larrea E; Espuelas S
J Dermatol Sci; 2018 Oct; 92(1):78-88. PubMed ID: 30037731
[TBL] [Abstract][Full Text] [Related]
27. [Miltefosine: a new remedy for leishmaniasis].
Dorlo TP; Eggelte TA; Beijnen JH; de Vries PJ
Ned Tijdschr Geneeskd; 2006 Dec; 150(49):2697-701. PubMed ID: 17194005
[TBL] [Abstract][Full Text] [Related]
28. Topical formulations of miltefosine for cutaneous leishmaniasis in a BALB/c mouse model.
Van Bocxlaer K; Yardley V; Murdan S; Croft SL
J Pharm Pharmacol; 2016 Jul; 68(7):862-72. PubMed ID: 27230300
[TBL] [Abstract][Full Text] [Related]
29.
Santos CC; Zhang H; Batista MM; de Oliveira GM; Demarque KC; da Silva-Gomes NL; Moreira OC; Ogungbe IV; Soeiro MNC
Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32928731
[TBL] [Abstract][Full Text] [Related]
30. Current scenario of drug development for leishmaniasis.
Croft SL; Seifert K; Yardley V
Indian J Med Res; 2006 Mar; 123(3):399-410. PubMed ID: 16778319
[TBL] [Abstract][Full Text] [Related]
31. Miltefosine efficiently eliminates Leishmania major amastigotes from infected murine dendritic cells without altering their immune functions.
Griewank K; Gazeau C; Eichhorn A; von Stebut E
Antimicrob Agents Chemother; 2010 Feb; 54(2):652-9. PubMed ID: 19995922
[TBL] [Abstract][Full Text] [Related]
32. Amiodarone and miltefosine act synergistically against Leishmania mexicana and can induce parasitological cure in a murine model of cutaneous leishmaniasis.
Serrano-Martín X; Payares G; De Lucca M; Martinez JC; Mendoza-León A; Benaim G
Antimicrob Agents Chemother; 2009 Dec; 53(12):5108-13. PubMed ID: 19805563
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of miltefosine treatment in Leishmania amazonensis-infected BALB/c mice.
Godinho JL; Simas-Rodrigues C; Silva R; Ürmenyi TP; de Souza W; Rodrigues JC
Int J Antimicrob Agents; 2012 Apr; 39(4):326-31. PubMed ID: 22226653
[TBL] [Abstract][Full Text] [Related]
34. Reductions in skin and systemic parasite burdens as a combined effect of topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) amazonensis.
Aguiar MG; Pereira AM; Fernandes AP; Ferreira LA
Antimicrob Agents Chemother; 2010 Nov; 54(11):4699-704. PubMed ID: 20713665
[TBL] [Abstract][Full Text] [Related]
35. Leishmania major: activity of tamoxifen against experimental cutaneous leishmaniasis.
Eissa MM; Amer EI; El Sawy SM
Exp Parasitol; 2011 Aug; 128(4):382-90. PubMed ID: 21620834
[TBL] [Abstract][Full Text] [Related]
36. Oleylphosphocholine (OlPC) arrests Cryptosporidium parvum growth in vitro and prevents lethal infection in interferon gamma receptor knock-out mice.
Sonzogni-Desautels K; Renteria AE; Camargo FV; Di Lenardo TZ; Mikhail A; Arrowood MJ; Fortin A; Ndao M
Front Microbiol; 2015; 6():973. PubMed ID: 26441906
[TBL] [Abstract][Full Text] [Related]
37. In vivo activity of perifosine against Leishmania amazonensis.
Cabrera-Serra MG; Valladares B; Piñero JE
Acta Trop; 2008 Oct; 108(1):20-5. PubMed ID: 18801328
[TBL] [Abstract][Full Text] [Related]
38. Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis.
Bhandari V; Kulshrestha A; Deep DK; Stark O; Prajapati VK; Ramesh V; Sundar S; Schonian G; Dujardin JC; Salotra P
PLoS Negl Trop Dis; 2012; 6(5):e1657. PubMed ID: 22629478
[TBL] [Abstract][Full Text] [Related]
39. Relapse after treatment with miltefosine for visceral leishmaniasis is associated with increased infectivity of the infecting Leishmania donovani strain.
Rai K; Cuypers B; Bhattarai NR; Uranw S; Berg M; Ostyn B; Dujardin JC; Rijal S; Vanaerschot M
mBio; 2013 Oct; 4(5):e00611-13. PubMed ID: 24105765
[TBL] [Abstract][Full Text] [Related]
40. Miltefosine to treat leishmaniasis.
Berman J
Expert Opin Pharmacother; 2005 Jul; 6(8):1381-8. PubMed ID: 16013987
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
